

1600
JC05 Rec'd PCT/PTO 2 3 OCT 2001IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): BOYLE, et al.

Serial No.: 09/613,591

Filed: JULY 10, 2000

For: COMBINATION THERAPY FOR CONDITIONS
LEADING TO BONE LOSS

Docket No.: A-378CIP5

Group Art Unit No.: 1647

Examiner: R. Deberry

JAN 0 1 2001

RECEIVED

JAN 0 2 2001

RECEIVED

RESPONSE TO NOTICE TO COMPLY AND AMENDMENTAssistant Commissioner for Patents
Washington, DC 20231

Sir:

This is in response to a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated September 28, 2001.

AMENDMENT

Please substitute the initial sequence listing with the attached amended sequence.

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same. The sequence listing submitted herewith contains no new matter.

Respectfully submitted,



Timothy J. Gaul
Attorney for Applicant
Registration No.: 33,111
Phone: (805) 447-2688
Date: October 23, 2001

Please send all future correspondence to:
US Patent Operations/ TJG
Dept. 430, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL198797425US

Date of Deposit: October 23, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Sherry St. Andrew
Printed Name

Sherry St. Andrew
Signature

Notice to Comply

Application No.

09/613,591

Examiner

Regina M. DeBerry

Applicant(s)

BOYLE ET AL.

Art Unit

1647

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY